AN AGREEMENT has been issued by the United States Centers for Disease Control and Prevention (CDC) to partner with Alveo Technologies to develop a rapid, point-of-need diagnostic test for detecting avian influenza A(H5) in humans. This innovative molecular diagnostic tool is designed to quickly and accurately differentiate between influenza A and B and the specific A/H5 virus, helping healthcare providers respond more effectively to potential outbreaks.
The CDC’s recent open call for industry collaboration highlighted the need for improved diagnostics to address the risks posed by avian influenza. Currently, testing capabilities for A/H5 in the U.S. are limited to CDC and select state laboratories, which could face challenges meeting demand if an outbreak occurs. Early and accessible diagnostics at the point of care are essential for minimizing virus spread, reducing diagnostic delays, and supporting timely treatment.
Alveo Technology’s (Alameda, California) portable diagnostic platform uses advanced isothermal nucleic acid amplification technology to deliver qualitative results on-site. This platform also allows for secure, real-time data reporting through a cloud-based system, enabling broader surveillance and efficient communication with public health officials. The multiplexed design can detect multiple influenza strains, including A/H5, from a single sample, enhancing clinical capabilities and improving pandemic response readiness.
As part of the CDC collaboration, Alveo aims to deploy this tool widely, increasing accessibility to frontline healthcare settings and relieving pressure on centralized laboratories.
“It is gratifying to be selected and enter this agreement to accelerate the development of our point of need diagnostic solutions for H5,” said Shaun Holt, CEO at Alveo Technologies. “We are proud to work with CDC to be a part of a national preparedness effort by enabling timely detection and response where it matters most – at the front lines of care.”
Reference: Alveo. Alveo Technologies Enters Agreement with CDC to Develop a Point of Need Spatial Multiplexed Test for Avian Influenza A(H5) Virus in Humans . November 14, 2024. Available at: https://www.alveotechnologies.com/news/alveo-technologies-enters-agreement-with-cdc-to-develop-a-point-of-need-spatial-multiplexed-test-for-avian-influenza-a-h5-virus-in-humans. Last accessed: November 14, 2024.
Anaya Malik | AMJ
